Login / Signup

Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Na v 1.7 for the Treatment of Pain.

Gregory L AdamsParul S PallSteven M GrauerXiaoping ZhouJeanine E BallardMarissa VavrekRichard L KrausPierre MorissetteNianyu LiStefania ColarussoElisabetta BianchiAnandan PalaniRebecca KleinChristopher T JohnDeping WangMatthew TudorAndrew F NoltingMirlinda BibaTimothy NowakAlexey A MakarovMikhail Y ReibarkhAlexei V BuevichWendy ZhongErik L RegaladoXiao WangQi GaoAurash ShahripourYuping ZhuDaniele de SimoneTommaso FrattarelliNicolo' Maria PasquiniPaola MagottiRoberto IaccarinoYuxing LiKelli SollyKeun-Joong LeeWeixun WangFeifei ChenHaoyu ZengJixin WangHilary ReganRupesh P AminChristopher P ReganChristopher S BurgeyDarrell A HenzeChengzao SunDavid M Tellers
Published in: Journal of medicinal chemistry (2021)
Inhibitor cystine knot peptides, derived from venom, have evolved to block ion channel function but are often toxic when dosed at pharmacologically relevant levels in vivo . The article describes the design of analogues of ProTx-II that safely display systemic in vivo blocking of Na v 1.7, resulting in a latency of response to thermal stimuli in rodents. The new designs achieve a better in vivo profile by improving ion channel selectivity and limiting the ability of the peptides to cause mast cell degranulation. The design rationale, structural modeling, in vitro profiles, and rat tail flick outcomes are disclosed and discussed.
Keyphrases